ArticleOncotarget2017
Methyl jasmonate leads to necrosis and apoptosis in hepatocellular carcinoma cells via inhibition of glycolysis and represses tumor growth in mice.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Allies or Enemies? The Power of Plant Hormones in Animals: Insights into Their Regulatory Roles.Molecules (Basel, Switzerland) · 2025Review
- Deciphering the Mysterious Relationship between the Cross-Pathogenetic Mechanisms of Neurodegenerative and Oncological Diseases.International journal of molecular sciences · 2023Review
- EZH2 activates Wnt/β-catenin signaling in human uterine fibroids, which is inhibited by the natural compound methyl jasmonate.F&S science · 2023Article
- Metabolism as a New Avenue for Hepatocellular Carcinoma Therapy.International journal of molecular sciences · 2023Review
- Current trends and future prospects of drug repositioning in gastrointestinal oncology.Frontiers in pharmacology · 2023Review
- Role of mitochondria-bound HK2 in rheumatoid arthritis fibroblast-like synoviocytes.Frontiers in immunology · 2023Article
- A probe-free electrochemical immunosensor for methyl jasmonate based on a Cu-MOF-carboxylated graphene oxide platform.RSC advances · 2022Article
- Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c-myc/hexokinase 2 pathway.Journal of cellular and molecular medicine · 2022Article
- Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.Acta pharmaceutica Sinica. B · 2022Review
- Therapeutic Potential of Jasmonic Acid and Its Derivatives.International journal of molecular sciences · 2021Review
- Jasmonate Compounds and Their Derivatives in the Regulation of the Neoplastic Processes.Molecules (Basel, Switzerland) · 2021Review
- Jasmonates induce Arabidopsis bioactivities selectively inhibiting the growth of breast cancer cells through CDC6 and mTOR.The New phytologist · 2021Article
- Tumor Decelerating and Chemo-Potentiating Action of Methyl Jasmonate on a T Cell LymphomaFrontiers in oncology · 2021Article
- Methyl Jasmonate Cytotoxicity and Chemosensitization of T Cell LymphomaFrontiers in pharmacology · 2021Article
- Proanthocyanidin B2 inhibits proliferation and induces apoptosis of osteosarcoma cells by suppressing the PI3K/AKT pathway.Journal of cellular and molecular medicine · 2020Article
- Natural Agents Targeting Mitochondria in Cancer.International journal of molecular sciences · 2020Review
- Salmonella enterica serovar Typhimurium sseK3 induces apoptosis and enhances glycolysis in macrophages.BMC microbiology · 2020Article
- Effect of methyl jasmonate and 3-bromopyruvate combination therapy on mice bearing the 4 T1 breast cancer cell line.Journal of bioenergetics and biomembranes · 2020Article
- Methyl Jasmonate Reduces Inflammation and Oxidative Stress in the Brain of Arthritic Rats.Antioxidants (Basel, Switzerland) · 2019Article
- Tumor metabolism regulating chemosensitivity in ovarian cancer.Genes & cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methyl jasmonate has recently been found to have anti-cancer activity. Methyl jasmonate detached hexokinase 2 from a voltage dependent anion channel causing a reduction in mitochondrial transmembrane potential that led to the release of cytochrome C and apoptosis inducing factor resulting in intrinsic apoptosis. Blocked adenosine triphosphate synthesis caused by mitochondrial injury hampered oxidative phosphorylation and led to cell necrosis. The results were applied to the in vivo treatment of nude mice with a satisfactory effect. Collectively, our results suggest that methyl jasmonate may be an adjuvant therapy for liver tumors due to its mechanism in cancer cells compared to that in normal cells: The major function is to inhibit glycolysis instead of changing aerobic metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.